Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HEPEDIAC
NCT05992077Active, not recruiting
- Sponsor
- ANRS
- Start
- Aug 2023
- Primary completion
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of sofosbuvir and daclatasvir in hepatitis C (HCV), sponsored by ANRS. Primary endpoint: Effectiveness of sofosbuvir/daclatasvir combination at 24 months. Started Aug 2023; status: active, not recruiting.
02
Drugs
sofosbuvirdaclatasvir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT05992077.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05992077.